XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Mar. 17, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 19, 2018
Revenues   $ 12,349,777 $ 13,071,800      
Net Income (Loss)   (459,863) 203,347      
Net cash used in operations   (6,344,173) (2,337,276)      
Working capital   32,083,333        
Accumulated deficit   (66,692,676)   $ (66,232,813)    
Stockholder equity   44,007,783 5,151,001 39,284,295 $ 4,379,463  
VAT net receivable and payable balance   243,424   79,373    
Allowance for doubtful accounts   7,614,237   7,309,311    
Cash on hand   6,995,287   0    
Depreciation expense   65,629 84,884      
Amortization expense   21,058 8,158      
Goodwill   49,697   $ 49,697   $ 49,697
Deferred revenue   $ 112,515        
Pharmaceuticals And Nutraceuticals Products License [Member]            
Estimated useful life   5 years        
Zip Doctor Inc [Member]            
Payment in cash $ 150,000          
ICC International Cannabis Corp [Member]            
Equity method investment aggregate cost   $ 0        
Equity method investment shares acquired, shares   3,000,000        
Closing price   $ 0        
National Bank of Greece [Member]            
Equity method investment aggregate cost   $ 8,099        
Equity method investment shares acquired, shares   16,666        
Closing price   $ 0.49        
Pancreta Bank [Member]            
Equity method investment aggregate cost   $ 8,333        
Greece [Member]            
Revenues   $ 11,914,231 $ 13,009,038      
Income tax rate   22.00%        
United Kingdom Of England [Member]            
Income tax rate   19.00%